Oncology News | pharmaphorum

News

Novartis calls time on Tim3 drug sabatolimab in MDS

Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate.

News

FDA starts swift review of tumour-agnostic use of Enhertu

AstraZeneca and Daiichi Sankyo’s Enhertu could become the first therapy approved by the FDA for use in any HER2-positive cancer, regardless of its location in the body.

News

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or

News

Keytruda improves survival in early-stage kidney cancer

MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell c

News

BMS' subcutaneous Opdivo clears first phase 3 trial

Bristol-Myers Squibb is getting closer to offering a subcutaneous version of its cancer immunotherapy Opdivo to patients after it matched the current intravenous formulati

News

Then there were two: ArriVent set to list after $175m IPO

ArriVent BioPharma was beaten to the first biotech initial public offering of the year when CG Oncology made its debut on the Nasdaq yesterday, but is due to start trading

Novartis calls time on Tim3 drug sabatolimab in MDS

FDA starts swift review of tumour-agnostic use of Enhertu

GSK’s Omjjara EU-cleared for splenomegaly in myelofibrosis

Keytruda improves survival in early-stage kidney cancer

BMS' subcutaneous Opdivo clears first phase 3 trial

Then there were two: ArriVent set to list after $175m IPO

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks